CN Patent

CN104884454B — 用作IL‑12、IL‑23和/或IFNα应答调节剂的酰胺取代的杂环化合物

Assigned to Bristol Myers Squibb Co · Expires 2017-11-28 · 8y expired

What this patent protects

具有下式I的化合物： 或其立体异构体或可药用盐，其中R 1 、R 2 、R 3 、R 4 和R 5 如本文所定义，其可通过作用于Tyk‑2以引起信号转导抑制，而用于调节IL‑12、IL‑23和/或IFNα。

USPTO Abstract

具有下式I的化合物： 或其立体异构体或可药用盐，其中R 1 、R 2 、R 3 、R 4 和R 5 如本文所定义，其可通过作用于Tyk‑2以引起信号转导抑制，而用于调节IL‑12、IL‑23和/或IFNα。

Drugs covered by this patent

Patent Metadata

Patent number
CN104884454B
Jurisdiction
CN
Classification
—
Expires
2017-11-28
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.